Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

1. Q3 2010 Investor Conference Call • Marijn Dekk
Science For A Better Life
Q3 2010 Results
Investor Conference Call
October 28 2010
Marijn Dekkers, CEO

2. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 2
Disclaimer
This presentation may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management.
Various known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. These
factors include those discussed in Bayer’s public reports which are available on the
Bayer website at www.bayer.com. The company assumes no liability whatsoever to
update these forward-looking statements or to conform them to future events or
developments.

3. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 3
Financial performance mainly driven by business expansion at MaterialScience
Emerging markets contributed 37% to group sales and continued strong business momentum
Xarelto – Rocket AF data presentation expected at upcoming AHA conference
€1.6bn lower net debt in the quarter
Full year 2010 group outlook reiterated
Third Quarter 2010 – Bayer Lifts Sales And Earnings Again

4. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 4
3rd Quarter 2010 –
Bayer Lifts Sales And Earnings Again
8,581
7,392
Sales
in € million
% portfolio & currency adj.
Q3´09 Q3´10
+8%
EBITDA
pre-special items
in € million
Q3´09 Q3´10
1,656
1,499
+10%
Core EPS
in €
Q3´09 Q3´10
0.950.78
+22%

5. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 5
Latin
America
Eastern
Europe
Africa &
Middle East
Emerging Economies
Emerging Markets Drive Growth And Contribute
Significantly to Group Sales
Emerging
Economies¹
+17%
Others²
-1%
USA
+3%
Emerging
Asia³
8%
37%
35%
20%
Western Europe
+6%
Group sales by region
Group €8,581m; +8%
~1,300
+23%
~1,100
+12%
~400
+23%
~400
+7%
¹ Emerging economies include: Latin America, Asia w/o Japan, Australia,
New Zealand, Africa and Middle East incl. Turkey, Eastern Europe
² Others = Japan, Australia, New Zealand, Canada
³ Emerging Asia = Asia minus Japan, Australia, New Zealand
In € million, Δ% yoy Fx
adjusted

6. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 6
-1.6
Cash Flow And Net Debt Development
Q3´10 Cash Flow Net Debt Development
GCF oFCF
879
Invest-
ments
395
In € billion
Q2´10 Q3´10
10.7
9.1
1,160
Δ %
y-o-y -25% +6%
NCF
cont.
1,555
+3%
In € million
-6%

7. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 7
HealthCare – Challenged US Pharma Business,
Ex-US Pharma Sales up 5%
Q3´10 Sales Earnings
Consumer
Health
+11% (+3%)
Pharma
+7% (0%)
1,539
2,732
HealthCare € 4,271m; +9% (+1%)
In € million, Δ% y-o-y, ( ) Fx & portfolio adj.
376
Q3´10
765
368
731 -4%
-2%
1,099 -4%
1,141
475
311 300
462 -3%
-4%
762 -3%786
Q3´10Q3´09
Underlying
EBITDA
Underlying
EBIT
Q3´09Price -1% Vol. 2% Fx 8% Portf. 0%

8. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 8
Expected Newsflow From Key Pharma Pipeline
Assets
2010
2011
Expected or upcoming major news flow:
Data AHA 2010eROCKET AF phase III trial in stroke prevention in A´fib patients
Q4 2010eVEGF Trap-Eye: First data from the VIEW phase III program in wet AMD
Q4 2010eFirst filings in DVT treatment and in stroke prevention in A´fib patients
Data expected early 2011MAGELLAN trial in VTE prevention in medically ill patients
Completion summer 2011eEINSTEIN-PE
Data expected 1H 2011VEGF Trap-Eye: Phase III program in CRVO
Beyond 2011Riociguat: Phase III in PAH and CTEPH
A´fib = atrial fibrillation
Completion summer 2011eATLAS TIMI 51

9. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 9
-16
CropScience – Solid Quarter,
Q4 Outlook Projects Higher Adjusted Sales
Q3´10 Sales Earnings
BioScience
+69% (+53%)
1,130
CropScience € 1,341m; +18% (+8%)
86 Crop Protection
+16% (+7%)
Environmental
Science
+8% (-3.5%)
125
118 142 +20%
126 +17%
108
-10
-16
Underlying
EBITDA
Underlying
EBIT
Q3´10Q3´09
12
33 +175%
-4 +75%
-28 -37
Q3´10Q3´09
-60%
-32%
Price 0% Vol. 9% Fx 9% Portf. 0%
In € million, Δ% y-o-y, ( ) Fx & portfolio adj.

10. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 10
Price 10% Vol. 13% Fx 8% Portf. 0%
Underlying
EBITDA
Q3´10Q3´09
409
Q3´10Q3´09
Underlying
EBIT
238
260
100
MaterialScience – Q3 Sales on, uEBITDA Above
Target, FY Financial Guidance Raised
Q3´10 Sales
Poly-
carbonates
+38% (+29%)
Polyurethanes
+31% (+23%)
726
Earnings
MaterialScience € 2,665m; +31% (+23%)
CAS*
+24% (+18%)
475
Industrial Operations
+21% (+17.5%)
143
1.321
* Coatings, Adhesives and Specialties
+72%
+160%
In € million, Δ% y-o-y, ( ) Fx & portfolio adj.

11. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 11
Full Year 2010 Group Outlook Projects Strong
Growth Over 2009
2009 Δ 2010E Q3 Update
Sales €31.2bn -6% >5% confirmed
uEBITDA €6.5bn -7% >€7bn confirmed
Core EPS €3.64 -13% >15% confirmed
Sales Fx and portfolio adjusted
Outlook depends on planning assumptions
as detailed in the 2009 annual report

12. Q3 2010 Investor Conference Call • Marijn Dekk
Science For A Better Life